Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases : a multinational retrospective cohort study
© 2023 The Author(s)..
Background: Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim was to characterise the incidence rates of AESIs following SARS-CoV-2 infection in patients and compare these to historical rates in the general population.
Methods: A multi-national cohort study with data from primary care, electronic health records, and insurance claims mapped to a common data model. This study's evidence was collected between Jan 1, 2017 and the conclusion of each database (which ranged from Jul 2020 to May 2022). The 16 pre-specified prevalent AESIs were: acute myocardial infarction, anaphylaxis, appendicitis, Bell's palsy, deep vein thrombosis, disseminated intravascular coagulation, encephalomyelitis, Guillain- Barré syndrome, haemorrhagic stroke, non-haemorrhagic stroke, immune thrombocytopenia, myocarditis/pericarditis, narcolepsy, pulmonary embolism, transverse myelitis, and thrombosis with thrombocytopenia. Age-sex standardised incidence rate ratios (SIR) were estimated to compare post-COVID-19 to pre-pandemic rates in each of the databases.
Findings: Substantial heterogeneity by age was seen for AESI rates, with some clearly increasing with age but others following the opposite trend. Similarly, differences were also observed across databases for same health outcome and age-sex strata. All studied AESIs appeared consistently more common in the post-COVID-19 compared to the historical cohorts, with related meta-analytic SIRs ranging from 1.32 (1.05 to 1.66) for narcolepsy to 11.70 (10.10 to 13.70) for pulmonary embolism.
Interpretation: Our findings suggest all AESIs are more common after COVID-19 than in the general population. Thromboembolic events were particularly common, and over 10-fold more so. More research is needed to contextualise post-COVID-19 complications in the longer term.
Funding: None.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 58(2023) vom: 01. Apr., Seite 101932 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Adverse events of special interest |
|---|
| Anmerkungen: |
Date Revised 24.04.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.eclinm.2023.101932 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355389886 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355389886 | ||
| 003 | DE-627 | ||
| 005 | 20231226064237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2023.101932 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355389886 | ||
| 035 | |a (NLM)37034358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Voss, Erica A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases |b a multinational retrospective cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background: Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim was to characterise the incidence rates of AESIs following SARS-CoV-2 infection in patients and compare these to historical rates in the general population | ||
| 520 | |a Methods: A multi-national cohort study with data from primary care, electronic health records, and insurance claims mapped to a common data model. This study's evidence was collected between Jan 1, 2017 and the conclusion of each database (which ranged from Jul 2020 to May 2022). The 16 pre-specified prevalent AESIs were: acute myocardial infarction, anaphylaxis, appendicitis, Bell's palsy, deep vein thrombosis, disseminated intravascular coagulation, encephalomyelitis, Guillain- Barré syndrome, haemorrhagic stroke, non-haemorrhagic stroke, immune thrombocytopenia, myocarditis/pericarditis, narcolepsy, pulmonary embolism, transverse myelitis, and thrombosis with thrombocytopenia. Age-sex standardised incidence rate ratios (SIR) were estimated to compare post-COVID-19 to pre-pandemic rates in each of the databases | ||
| 520 | |a Findings: Substantial heterogeneity by age was seen for AESI rates, with some clearly increasing with age but others following the opposite trend. Similarly, differences were also observed across databases for same health outcome and age-sex strata. All studied AESIs appeared consistently more common in the post-COVID-19 compared to the historical cohorts, with related meta-analytic SIRs ranging from 1.32 (1.05 to 1.66) for narcolepsy to 11.70 (10.10 to 13.70) for pulmonary embolism | ||
| 520 | |a Interpretation: Our findings suggest all AESIs are more common after COVID-19 than in the general population. Thromboembolic events were particularly common, and over 10-fold more so. More research is needed to contextualise post-COVID-19 complications in the longer term | ||
| 520 | |a Funding: None | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse events of special interest | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a OMOP CDM | |
| 650 | 4 | |a Observational research | |
| 700 | 1 | |a Shoaibi, Azza |e verfasserin |4 aut | |
| 700 | 1 | |a Yin Hui Lai, Lana |e verfasserin |4 aut | |
| 700 | 1 | |a Blacketer, Clair |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Thamir |e verfasserin |4 aut | |
| 700 | 1 | |a Makadia, Rupa |e verfasserin |4 aut | |
| 700 | 1 | |a Haynes, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Sena, Anthony G |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Gowtham |e verfasserin |4 aut | |
| 700 | 1 | |a van Sandijk, Sebastiaan |e verfasserin |4 aut | |
| 700 | 1 | |a Fraboulet, Clement |e verfasserin |4 aut | |
| 700 | 1 | |a Boyer, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Le Carrour, Tanguy |e verfasserin |4 aut | |
| 700 | 1 | |a Horban, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Daniel R |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Roldán, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Anguita, Juan Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a de Wilde, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a John, Luis H |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte-Salles, Talita |e verfasserin |4 aut | |
| 700 | 1 | |a Roel, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pistillo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Kolde, Raivo |e verfasserin |4 aut | |
| 700 | 1 | |a Maljković, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Denaxas, Spiros |e verfasserin |4 aut | |
| 700 | 1 | |a Papez, Vaclav |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Natarajan, Karthik |e verfasserin |4 aut | |
| 700 | 1 | |a Reich, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Secora, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Minty, Evan P |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nigam H |e verfasserin |4 aut | |
| 700 | 1 | |a Posada, Jose D |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia Morales, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Bosca, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Cadenas Juanino, Honorio |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz Holgado, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrera Jiménez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano Balazote, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a García Barrio, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Şen, Selçuk |e verfasserin |4 aut | |
| 700 | 1 | |a Üresin, Ali Yağız |e verfasserin |4 aut | |
| 700 | 1 | |a Erdogan, Baris |e verfasserin |4 aut | |
| 700 | 1 | |a Belmans, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Byttebier, Geert |e verfasserin |4 aut | |
| 700 | 1 | |a Malbrain, Manu L N G |e verfasserin |4 aut | |
| 700 | 1 | |a Dedman, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Cuccu, Zara |e verfasserin |4 aut | |
| 700 | 1 | |a Vashisht, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Butte, Atul J |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Ayan |e verfasserin |4 aut | |
| 700 | 1 | |a Dahm, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Cora |e verfasserin |4 aut | |
| 700 | 1 | |a Bu, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Arshad, Faaizah |e verfasserin |4 aut | |
| 700 | 1 | |a Ostropolets, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Nyberg, Fredrik |e verfasserin |4 aut | |
| 700 | 1 | |a Hripcsak, George |e verfasserin |4 aut | |
| 700 | 1 | |a Suchard, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto-Alhambra, Dani |e verfasserin |4 aut | |
| 700 | 1 | |a Rijnbeek, Peter R |e verfasserin |4 aut | |
| 700 | 1 | |a Schuemie, Martijn J |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Patrick B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d 2018 |g 58(2023) vom: 01. Apr., Seite 101932 |w (DE-627)NLM289300495 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2023 |g day:01 |g month:04 |g pages:101932 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eclinm.2023.101932 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2023 |b 01 |c 04 |h 101932 | ||